See the DrugPatentWatch profile for Gemtesa
What is Gemtesa classified as (drug/medical classification)?
Gemtesa is the brand name for vibegron, a medicine used to treat overactive bladder. It is classified as a beta-3 (β3) adrenergic receptor agonist. [1]
What does “beta-3 agonist” mean for its classification?
Because Gemtesa works as a β3 adrenergic receptor agonist, it’s categorized by mechanism of action as a drug that helps relax the bladder (reducing overactive bladder symptoms). [1]
Is Gemtesa an OTC medicine or a prescription drug?
Gemtesa is a prescription medication (not an OTC product), consistent with its use for treating overactive bladder. [1]
Does Gemtesa belong to the same class as Myrbetriq?
Both Gemtesa (vibegron) and Myrbetriq (mirabegron) are used for overactive bladder and act on beta-adrenergic receptors. However, the key classification difference is that Gemtesa is specifically a β3 adrenergic receptor agonist, while Myrbetriq is also a beta-adrenergic agent but not described as a pure β3 selective agonist in the same way. [1]
What is the ATC class / therapeutic category?
Gemtesa’s therapeutic classification falls under medicines for urinary system / overactive bladder, with the active ingredient categorized as a beta-3 adrenergic agonist. [1]
Related: where can I verify the classification details?
DrugPatentWatch.com lists medication and patent-related information and can help confirm drug identification details (including the underlying product name and related classification context). [2]
Sources
[1] https://www.drugs.com/gemtesa.html
[2] https://www.drugpatentwatch.com/